Prestige Consumer Healthcare (PBH) Change in Account Payables (2010 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Change in Account Payables came in at -$4.1 million in Q4 2025, up 63.68% year-on-year from -$2.5 million in Q4 2024, and down 120.66% quarter-over-quarter from $19.8 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Change in Account Payables (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Change in Account Payables history runs 16 years deep, the most recent figure standing at -$4.1 million for Q4 2025.
- On a quarterly basis, Change in Account Payables rose 63.68% year-over-year to -$4.1 million in Q4 2025; TTM through Dec 2025 was $17.9 million, a 190.12% increase from a year earlier, with the FY2025 full-year figure at -$19.4 million, up 22.27% from the prior year.
- Change in Account Payables fell to -$4.1 million in Q4 2025 per PBH's latest filing, from $19.8 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $19.8 million in Q3 2025 and bottomed at -$15.6 million in Q2 2021.
- The 5-year median for Change in Account Payables is -$783500.0 (2024), against an average of $446700.0.
- Across the five-year window, Change in Account Payables tumbled 766.38% in 2023 and surged 366.33% in 2025, its largest moves.
- Year by year, Change in Account Payables stood at $2.2 million in 2021, then soared by 258.65% to $7.9 million in 2022, then tumbled by 165.31% to -$5.1 million in 2023, then sank by 118.8% to -$11.3 million in 2024, then surged by 63.68% to -$4.1 million in 2025.
- Per Business Quant, the three latest PBH Change in Account Payables figures stand at -$4.1 million (Q4 2025), $19.8 million (Q3 2025), and $2.8 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.55 Bn | 87.69 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.45 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Prestige Consumer Healthcare | 2.44 Bn | 2.38 Bn | 157.37 Mn | -4.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.09 Mn |
| Dec 31, 2025 | -4.09 Mn |
| Sep 30, 2025 | 19.79 Mn |
| Sep 30, 2025 | 19.79 Mn |
| Jun 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 2.76 Mn |
| Mar 31, 2025 | -560,000.00 |
| Mar 31, 2025 | -560,000.00 |
| Dec 31, 2024 | -11.26 Mn |
| Dec 31, 2024 | -11.26 Mn |
| Sep 30, 2024 | -8.19 Mn |
| Sep 30, 2024 | -8.19 Mn |
| Jun 30, 2024 | 591,000.00 |
| Jun 30, 2024 | 591,000.00 |
| Mar 31, 2024 | -1.01 Mn |
| Mar 31, 2024 | -1.01 Mn |
| Dec 31, 2023 | -5.14 Mn |
| Dec 31, 2023 | -5.14 Mn |
| Sep 30, 2023 | -13.22 Mn |
| Sep 30, 2023 | -13.22 Mn |